Back
Open Access

Impact of treatment modality on prognostic features in patients with severe tricuspid regurgitation

Session: Cutting edge transcatheter heart failure therapeutics
Topic: Intervention
Speaker: Doctor K. Kresoja (Mainz, DE)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Karl-Patrik Kresoja

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)
4 presentations
0 follower

5 more presentations in this session

Tricuspid regurgitation in patients undergoing mitral valve surgery for primary mitral regurgitation

Speaker: Assistant Professor K. Lodin (Stockholm, SE)

Access
Abstract
Like
Thumbnail

Risk assessment in patients with low-flow, low-gradient aortic stenosis undergoing TAVI

Speaker: Doctor M. Caetano Coelho (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Two-year outcomes of mitral transcatheter edge-to-edge repair in patients with heart failure and functional mitral regurgitation from the MiCLASP Study

Speaker: Doctor K. Rommel (Mainz, DE)

Access
Abstract
Like
Thumbnail

Impact of ejection fraction based heart failure classification on TAVI related outcomes

Speaker: Doctor Y. Sener (Rotterdam, NL)

Access
Abstract
Like
Thumbnail

De novo conduction disturbances after TAVI: what to expect?

Speaker: Doctor D. Da Silva Correia (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

Cutting edge transcatheter heart failure therapeutics

Speakers: Doctor K. Kresoja, Assistant Professor K. Lodin, Doctor M. Caetano Coelho, Doctor K. Rommel, Doctor Y. Sener...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources